CN114642639A - 一种枸橼酸托法替布缓释组合物及其制备方法 - Google Patents
一种枸橼酸托法替布缓释组合物及其制备方法 Download PDFInfo
- Publication number
- CN114642639A CN114642639A CN202011508819.0A CN202011508819A CN114642639A CN 114642639 A CN114642639 A CN 114642639A CN 202011508819 A CN202011508819 A CN 202011508819A CN 114642639 A CN114642639 A CN 114642639A
- Authority
- CN
- China
- Prior art keywords
- release
- tofacitinib citrate
- sustained
- pharmaceutical composition
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 title claims abstract description 85
- 229960004247 tofacitinib citrate Drugs 0.000 title claims abstract description 71
- 238000013268 sustained release Methods 0.000 title claims abstract description 44
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 239000008187 granular material Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000002775 capsule Substances 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000003085 diluting agent Substances 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000011812 mixed powder Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229940069328 povidone Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003405 delayed action preparation Substances 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 229960001375 lactose Drugs 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000007939 sustained release tablet Substances 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229960001681 croscarmellose sodium Drugs 0.000 description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
- 239000004012 Tofacitinib Substances 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 229940085605 saccharin sodium Drugs 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940039916 xeljanz Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及枸橼酸托法替布缓释组合物及其制备方法，其药物组合物包括活性成分枸橼酸托法替布、缓释材料、溶剂、稀释剂，该药物组合物可通过添加其它药学上可接受的辅料制备胶囊剂和颗粒剂，可实现8~12h的缓释效果，释放稳定，制备周期短，工艺简单，重现性高，适合大生产。本品可以减少患者的服药次数，缓释剂适合不同人群服用。
Description
技术领域
本发明涉及药物制剂领域，具体涉及一种枸橼酸托法替布缓释组合物及其制备方法。
背景技术
枸橼酸托法替布（Tofacitinib Citrate），化学名为：3-((3R ,4R)-4-甲基-3-(甲基(7H-吡咯并[2 ,3-d]嘧啶-4-基)氨基派啶-1-基)-3-氧代丙腈，结构式如下：
枸橼酸托法替布是一种JAK激酶抑制剂，其用于甲氨蝶呤疗效不理想或对甲氨蝶呤过敏的中度至重度类风湿性关节炎成年人患者，是开发用于类风湿性关节炎治疗的首创药物。枸橼酸托法替布制剂最早由美国辉瑞公司研发推出，商品名：XELJANZ，包括5mg和10mg规格的速释片和1mg/mL规格口服溶液；商品名XELJANZ XR，包括11mg和22mg规格的缓释片。
关于枸橼酸托法替布的缓释制剂，已有诸多技术文献公开发表，例如XELJANZ XR原研专利WO2014/147526A1公开的一种枸橼酸托法替布缓释片是通过渗透泵膜实现缓释效果，其释放标准为在pH6.8介质，50rpm条件下释放度要求为1h：≤25%，2.5h：40~70%，5h＞75%。其制备工艺包括挤出滚圆制粒、混合、压片、半透膜包衣、约16h的老化，整个工艺流程工序复杂，耗时长。在其基础上，专利CN111184696A采用溶蚀性骨架材料和亲水凝胶骨架材料联用，将活性成分枸橼酸托法替布与骨架材料共同熔融，冷却固化后研磨过筛，制备成载药颗粒后压片制备成缓释片，在pH6.8磷酸盐缓冲液中可实现6-12h的缓释效果，但其3~6h的释放速度略快于XELJANZ XR。专利CN108066319 A同样采用溶蚀性骨架材料或非溶蚀性骨架材料和亲水凝胶骨架材料联用，采用挤出滚圆制粒、干燥24小时，筛分小丸后肠溶包衣（含老化12h）制备缓释微丸，灌装胶囊，可实现12~24h的释放，因其具有长效释放效果，故5h后的释放比XELJANZ XR释放更慢。由于两个专利中均未给出其制剂的体内吸收数据，故无法获知这样的与XELJANZ XR释放的差异是否会影响其药物在体内的吸收进而影响药效。专利CN110787145 A提供了一种采用普通湿法制粒制备的半透膜控型缓释片，其释放速率与XELJANZ XR较为接近，但其缓释技术除控制片芯形状及大小外，片剂包衣工艺也是影响其缓释能力的关键因素，故该专利工艺仅适用于片剂，无法应用于胶囊剂或者颗粒剂。
因此，本领域仍期待有新的方法来制备可应用于更多剂型的枸橼酸托法替布的缓释药物组合物，特别是采用工艺易控、对设备需求更低的工艺来制备枸橼酸托法替布药物组合物，且应用其采用传统的制粒工艺制备胶囊剂、颗粒剂或者片剂，能够与XELJANZ XR有着相似的体外释放行为。
发明内容
为了在不同剂型中实现与XELJANZ XR有相似缓释效果的制剂的目的，本发明采用单一骨架缓释材料，对活性成分枸橼酸托法替布进行颗粒包衣制备具有缓释能力的药物组合物，再将该药物组合物与填充剂、润滑剂、助流剂、崩解剂、矫味剂等辅料通过传统的混合或制粒工艺，经充填或者分装后制备成胶囊剂或者颗粒剂。该工艺生产周期短，可控性强，对于设备要求较低，制备的制剂与XELJANZ XR具有相似的体外释放行为。具体地，本发明中的技术方式是这样实现的：
本发明涉及一种枸橼酸托法替布缓释组合物，所述的药物组合物应用于制备缓释颗粒剂及缓释胶囊剂。
具体地，所述的枸橼酸托法替布缓释组合物其特征在于包括活性成分枸橼酸托法替布、缓释材料、溶剂、稀释剂，通过颗粒包衣技术制备成缓释药物组合物。
用于评价该组合物制备的制剂的体外释放行为的实验方法为：参照释放度测定法（中国药典2015版四部制剂通则0931第二法）+沉降篮的装置，释放介质为pH6.8磷酸盐缓冲液900ml，转速为每分钟50rpm。
用于评价该组合物制备的制剂的体外释放行为的释放标准为：释放度达到1h：≤25%（w），2.5h：40~70%（w），5h＞75%（w）。
进一步地，所述的活性成分枸橼酸托法替布在制剂处方中所占的重量比为8%~12%；
进一步地，所述的枸橼酸托法替布制剂活性成分优选规格为11mg和22mg。
此外，所述的缓释材料选自聚维酮（PVP）、羟丙基纤维素（HPC）、羟丙甲纤维素（HPMC）、乙基纤维素（EC）中的一种，在制剂处方中所占的重量比为5%~15%。
优选地，所述的聚维酮优选PVP K90，羟丙基纤维素优选 HPC HF或HXF，羟丙甲纤维素优选HPMC K系列，乙基纤维素优选RTN7或10。
对于缓释材料的用量优选，发明人以枸橼酸托法替布含量为11.9%（规格11mg）的胶囊剂剂为例，采用不同的缓释材料及用量，考察制备的药物组合物在pH6.8磷酸盐缓冲液900ml，转速为每分钟50rpm条件下，1h、2.5h、5h和12h的释放度。
表
不同缓释材料用量对组合物体外释放的影响
结果显示，缓释材料在制剂处方中优选用量比为8~12%。
此外，溶剂为水、乙醇或乙醇和水的任意比混合液，用于配制缓释材料溶液。
此外，稀释剂包括山梨醇、甘露醇、乳糖、微晶纤维素中的一种或几种，在制剂处方中所占的重量比为20~40%。
所述的枸橼酸托法替布药物组合物，其制备方法包括如下步骤：（1）将缓释材料用溶剂配制成稀溶液，（2）将枸橼酸托法替布和稀释剂混合均匀，得到药物混粉；（3）用流化床向药物混粉中喷入缓释材料溶液，进行颗粒包衣，干燥后过24~30目筛网整粒，得到枸橼酸托法替布药物组合物。
所述的枸橼酸托法替布药物组合物，可通过添加其它药学上可接受的辅料，通过湿法制粒、流化制粒或者混合工艺制备成颗粒剂或胶囊剂，其中所述的其它药学上可接受的辅料包括但不限于填充剂、粘合剂、润滑剂、崩解剂、矫味剂中的一种或几种。
进一步地，所述的填充剂包括山梨醇、甘露醇、乳糖、微晶纤维素、淀粉、壳聚糖中的一种或几种；
进一步地，所述的润滑剂包括硬脂酸镁、硬脂酸、硬脂富马酸钠、滑石粉、胶态二氧化硅中的一种或几种；
进一步地，所述的粘合剂包括聚维酮、羟丙甲纤维素、羧甲基纤维素钠、羟丙纤维素中的一种或几种；
进一步地，所述的崩解剂包括交联羧甲基纤维素钠、交联聚维酮、羧甲基淀粉钠、低取代羟丙纤维素中的一种；
进一步地，所述的矫味剂包括糖精钠、蔗糖、阿斯巴甜的一种与不同口味的香精配合使用。
有益效果：本发明是采用单一骨架缓释材料，对活性成分枸橼酸托法替布进行颗粒包衣制备具有缓释能力的药物组合物，再将该药物组合物与其它药物辅料采用工艺易控、对设备需求更低的传统制粒工艺来制备枸橼酸托法替布制剂，且应用其制备胶囊剂、颗粒剂能够与XELJANZ XR有着相似的体外释放行为，实现了在不同剂型中实现与XELJANZ XR有相似缓释效果的制剂的目的，该工艺整个生产过程未使用本领域现阶段常用的滚圆制粒或者肠溶包衣，因此生产周期大大缩短，且可控性强，对于设备要求也较低。
具体实施方式
下面结合实施例对本发明做进一步的详细说明，但以下实施例仅用于说明本发明，不作为对本发明的限制。
实施例1枸橼酸托法替布缓释组合物的制备
枸橼酸托法替布……17.8g
羟丙甲纤维素……11.0g
水……300g
山梨醇……51.2
————共制成80.0g
将羟丙甲纤维素加入至纯化水中配制成稀溶液，将枸橼酸托法替布和山梨醇混合均匀，得到药物混粉；用流化床向药物混粉中喷入羟丙甲纤维素水溶液，进行颗粒包衣，干燥后过30目筛网整粒，得到枸橼酸托法替布药物组合物。
实施例2枸橼酸托法替布缓释组合物的制备
枸橼酸托法替布……17.8g
聚维酮……17.0 g
50%乙醇-水溶液……200.0 g
微晶纤维素……45.2 g
————共制成80.0g
将聚维酮加入至50%乙醇-水溶液中配制成稀溶液，将枸橼酸托法替布和微晶纤维素混合均匀，得到药物混粉；用流化床向药物混粉中喷入聚维酮K30乙醇水溶液，进行颗粒包衣，干燥后过30目筛网整粒，得到枸橼酸托法替布药物组合物。
实施例3枸橼酸托法替布缓释组合物的制备
枸橼酸托法替布……35.5g
乙基纤维素……40.0g
乙醇……200.0g
乳糖……44.5g
————共制成100g
将乙基纤维素加入至乙醇中配制成稀溶液，将枸橼酸托法替布和乳糖混合均匀，得到药物混粉；用流化床向药物混粉中喷入乙基纤维素醇溶液，进行颗粒包衣，干燥后过24目筛网整粒，得到枸橼酸托法替布药物组合物。
实施例4枸橼酸托法替布缓释组合物的制备
枸橼酸托法替布……35.5g
羟丙纤维素……18.0 g
水……360 g
甘露醇……11.0 g
山梨醇……35.5 g
————共制成100g
将乙基纤维素加入至乙醇中配制成稀溶液，将枸橼酸托法替布和乳糖混合均匀，得到药物混粉；用流化床向药物混粉中喷入乙基纤维素醇溶液，进行颗粒包衣，干燥后过24目筛网整粒，得到枸橼酸托法替布药物组合物。
实施例5枸橼酸托法替布缓释胶囊的制备（规格：11mg）
枸橼酸托法替布缓释组合物（实施例1）……80.0g
乳糖……49.0g
微晶纤维素……16.5g
羟丙甲纤维素……1.5g
交联羧甲基纤维素钠……1.5g
纯化水……30.0g
滑石粉……1.5g
————共制成1000粒
将羟丙甲纤维素用纯化水配制成粘合剂溶液，枸橼酸托法替布缓释组合物与乳糖、微晶纤维素、交联羧甲基纤维素钠混合均匀，加入粘合剂溶液湿法制粒，40~50℃干燥，整粒后加入滑石粉，充填胶囊即得。
实施例6枸橼酸托法替布缓释颗粒的制备（规格：11mg）
枸橼酸托法替布缓释组合物（实施例2）……80.0g
山梨醇……65.4g
聚维酮……3.0g
纯化水……30.0g
硬脂酸镁……1.5g
糖精钠……0.1g
————共制成1000粒
将聚维酮用纯化水配制成粘合剂溶液，枸橼酸托法替布缓释组合物与山梨醇和糖精钠混合均匀，加入粘合剂溶液高剪切制粒，40~50℃干燥，整粒后加入硬脂酸镁，即得。
实施例7枸橼酸托法替布缓释胶囊的制备（规格：22mg）
枸橼酸托法替布缓释组合物（实施例3）……100.0g
乳糖……223.0g
交联聚维酮……4.0
预胶化淀粉……45.0g
纯化水……适量
滑石粉……8.0g
————共制成1000粒
将枸橼酸托法替布缓释组合物与乳糖、预胶化淀粉、交联聚维酮混合均匀，加入纯化水溶液制粒，40~50℃干燥，整粒后加入滑石粉，充填胶囊即得。
实施例8为了进一步说明使用本发明中的先将枸橼酸托法替布制备成缓释组合物，再制备成制剂的工艺的优势，结合实施例1和实施例5处方，发明人对制备工艺进行了如下尝试：
枸橼酸托法替布……17.8g
羟丙甲纤维素……11.5g
山梨醇……51.2
乳糖……49.0g
微晶纤维素……16.5g
交联羧甲基纤维素钠……1.5g
纯化水……500.0g
滑石粉……1.5g
————共制成1000粒
将羟丙甲纤维素用纯化水配制成粘合剂溶液，枸橼酸托法替布缓释组合物与乳糖、微晶纤维素、交联羧甲基纤维素钠混合均匀，喷入粘合剂溶液流化制粒，干燥、整粒后加入滑石粉，充填胶囊即得。
实施例9 为了进一步说明使用本发明的技术特点，根据已有专利技术制备如下处方作为对比例研究：
对比例1市售XELJANZ XR，规格11mg，来源：辉瑞制药。
对比例2枸橼酸托法替布缓释片，规格11mg，处方工艺同专利CN111184696A。
对比例3枸橼酸托法替布缓释片，规格11mg，处方工艺同专利CN108066319A。
实施例10枸橼酸托法替布缓释制剂的释放度测定
用于评价该组合物制备的制剂的体外释放行为的实验方法为：参照释放度测定法（中国药典2015版四部制剂通则0931第二法）+沉降篮的装置，释放介质为pH6.8磷酸盐缓冲液900ml，转速为每分钟50rpm。
用于评价该组合物制备的制剂的体外释放行为的释放标准为：释放度达到1h：≤25%（w），2.5h：40~70%（w），5h＞75%（w）。
表
各实施例释放结果
实施例5~7与实施例8的对比结果表明，本发明中先将枸橼酸托法替补采用颗粒包衣的方法制备成缓释组合物，再制备成缓释制剂，比直接将枸橼酸托法替布、缓释材料及其他辅料一次性制备成制粒，缓释效果更好。
实施例5~7与对比例1、2、3的对比结果表明，采用本发明技术制备的胶囊机和颗粒剂与已有上市原研制剂XELJANZ XR有更为相似的体外释放曲线。
Claims (5)
1.一种枸橼酸托法替布缓释药物组合物，其特征在于包括活性成分枸橼酸托法替布、缓释材料、溶剂、稀释剂，通过颗粒包衣技术制备成缓释药物组合物，其缓释药物组合物可用于制备缓释颗粒剂及缓释胶囊剂。
2.根据权利要求1所述的枸橼酸托法替布药物组合物，其特征在于所述的活性成分枸橼酸托法替布在制剂处方中所占的重量比为8%~12%；缓释材料选自聚维酮、羟丙基纤维素、羟丙甲纤维素、乙基纤维素中的一种，在制剂处方中所占的重量比为5%~15%；溶剂为水、乙醇或乙醇和水的任意比混合液，用于配制缓释材料溶液，稀释剂包括山梨醇、甘露醇、乳糖、微晶纤维素中的一种或几种，在制剂处方中所占的重量比为20~40%。
3.根据权利要求2所述的枸橼酸托法替布药物组合物，其特征在于其制备方法包括如下步骤：将缓释材料用溶剂配制成稀溶液，将枸橼酸托法替布和稀释剂混合均匀，得到药物混粉；用流化床向药物混粉中喷入缓释材料溶液，进行颗粒包衣，干燥后过24~30目筛网整粒，得到枸橼酸托法替布药物组合物。
4.根据权利要求3所述的枸橼酸托法替布药物组合物，其特征在于可通过添加其它药学上可接受的辅料，通过湿法制粒、流化制粒或者混合工艺制粒，经充填或者分装后制备成胶囊剂或者颗粒剂。
5.根据权利要求3所述的枸橼酸托法替布药物组合物，其特征在于所述的其它药学上可接受的辅料包括但不限于填充剂、粘合剂、润滑剂、崩解剂、矫味剂中的一种或几种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011508819.0A CN114642639A (zh) | 2020-12-18 | 2020-12-18 | 一种枸橼酸托法替布缓释组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011508819.0A CN114642639A (zh) | 2020-12-18 | 2020-12-18 | 一种枸橼酸托法替布缓释组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114642639A true CN114642639A (zh) | 2022-06-21 |
Family
ID=81990936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011508819.0A Pending CN114642639A (zh) | 2020-12-18 | 2020-12-18 | 一种枸橼酸托法替布缓释组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114642639A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068432A (zh) * | 2022-08-02 | 2022-09-20 | 沈阳信康药物研究有限公司 | 一种枸橼酸托法替布压制包衣缓释片及其制备方法 |
| CN115887408A (zh) * | 2022-11-29 | 2023-04-04 | 江苏慧聚药业股份有限公司 | 包含托法替布的药物组合物和药物制剂 |
-
2020
- 2020-12-18 CN CN202011508819.0A patent/CN114642639A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115068432A (zh) * | 2022-08-02 | 2022-09-20 | 沈阳信康药物研究有限公司 | 一种枸橼酸托法替布压制包衣缓释片及其制备方法 |
| CN115887408A (zh) * | 2022-11-29 | 2023-04-04 | 江苏慧聚药业股份有限公司 | 包含托法替布的药物组合物和药物制剂 |
| CN115887408B (zh) * | 2022-11-29 | 2024-05-24 | 江苏慧聚药业股份有限公司 | 包含托法替布的药物组合物和药物制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1027037B1 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| JP4616009B2 (ja) | ＮＳＡＩＤｓおよびトリプタンを含有する多層剤型 | |
| EP2331074B1 (en) | Granulates, process for preparing them and pharmaceutical products containing them | |
| JP6173521B2 (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
| US7976869B2 (en) | Fenofibrate tablets | |
| CN110062628B (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| KR20200082006A (ko) | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 | |
| CN114642639A (zh) | 一种枸橼酸托法替布缓释组合物及其制备方法 | |
| US6482437B2 (en) | Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations | |
| US20090088424A1 (en) | Methods and compositions for controlling the bioavailability of poorly soluble drugs | |
| EP1061803B1 (en) | Compositions of eprosartan | |
| WO2021160608A1 (en) | Pharmaceutical composition comprising linagliptin and metformin | |
| US20100035846A1 (en) | Method for the treatment of acne and certain dosage forms thereof | |
| CN114146089B (zh) | 含依非韦伦、替诺福韦和恩曲他滨的药物组合物 | |
| TW202300155A (zh) | 一種托法替布緩釋製劑及其製備方法 | |
| WO2006003587A2 (en) | Solid oral dosage forms of azabicyclo derivatives | |
| JP2000516601A (ja) | 水溶性化合物及びセルロースを含有する粒状物 | |
| CN114053421A (zh) | 一种血小板生成素受体激动剂的组合物及其制备方法 | |
| JP6618595B1 (ja) | カフェインおよびヒヨスチアミン含有医薬組成物およびその製造方法 | |
| JP2006509789A (ja) | 不安症治療法及び治療薬 | |
| KR20160141045A (ko) | 보센탄을 함유한 약학적 조성물 | |
| KR20190076711A (ko) | 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법 | |
| CN115212176A (zh) | 泽布替尼缓释片剂 | |
| WO2011027322A1 (en) | Extended release dosage form containing olopatadine for oral administration | |
| JP2003300874A (ja) | 塩酸プソイドエフェドリン含有固形製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |